Increasing Incidence of Hypercoagulability to Propel the Growth of Market at 7% CAGR through 2033. The Asia Pacific Hypercoagulability Treatment Market is expected to exhibit the significant ...

Hypercoagulability in patients with COVID-19 by American Roentgen Ray Society A, 76-year-old woman who presented to emergency department with upper back pain.

Based on a meta-analysis of trials, rebound hypercoagulability accounts for about 2% of patients having recurrent venous thromboembolism in the first 2 months after discontinuing oral anticoagulants.

Results: Hypercoagulability was present at treatment start in 40% of patients. Median baseline fibrinogen was 6.2 mg/dl. Serious disorders were found in 68% of patients. Abnormal coagulation was ...

Roland von Känel, Brigitte M. Kudielka, Renate Schulze, Marie-Louise Gander, Joachim E. Fischer, Hypercoagulability in Working Men and Women with High Levels of Panic-Like Anxiety, Psychotherapy and ...

In this AJR article, 82 patients with COVID-19 who underwent abdominal ultrasound or CT were retrospectively compared with 82 patients without COVID-19 for thromboembolism and solid-organ ...

The global hypercoagulability treatment market is expected to garner a market value of US$ 670 million in 2023 and is expected to accumulate a market value of US$ 1,317.99 million by registering a ...

TCT 1256: Malignancy-Induced Hypercoagulability: A Precipitating Factor in Acute Stent Thrombosis ...

According to market research, the Hypercoagulability Treatment industry will be worth US$ 670 million in 2023 and US$ 1,317.99 million by 2033, growing at a CAGR of 7% over the projected period. The ...